Cargando…

The EGFR Inhibitor Gefitinib Enhanced the Response of Human Oral Squamous Cell Carcinoma to Cisplatin In Vitro

INTRODUCTION: The epidermal growth factor receptor (EGFR) is highly expressed in a variety of solid tumors including oral cavity squamous cell carcinoma (OSCC) and has been implicated in the resistance of these tumors to cisplatin. This study was performed to determine if the EGFR tyrosine kinase in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khalil, Ashraf, Jameson, Mark J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2017
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5694417/ https://www.ncbi.nlm.nih.gov/pubmed/28828595 http://dx.doi.org/10.1007/s40268-017-0204-x

Ejemplares similares

EGFR Inhibitor Enhances Cisplatin Sensitivity of Oral Squamous Cell Carcinoma Cell Lines
por: Hiraishi, Yukihiro, et al.
Publicado: (2008)

BST2 promotes growth and induces gefitinib resistance in oral squamous cell carcinoma via regulating the EGFR pathway
por: Jin, Huang, et al.
Publicado: (2019)

Gimeracil enhances the antitumor effect of cisplatin in oral squamous cell carcinoma cells in vitro and in vivo
por: Harada, Koji, et al.
Publicado: (2017)

Synergetic Effects of PARP Inhibitor AZD2281 and Cisplatin in Oral Squamous Cell Carcinoma in Vitro and in Vivo
por: Yasukawa, Masaaki, et al.
Publicado: (2016)

Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells
por: Li, Amin, et al.
Publicado: (2020)

Inhibition of DNA-PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC
por: Pan, Chi, et al.
Publicado: (2020)

Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib
por: Yuan, Ying, et al.
Publicado: (2012)

Naa10p Enhances Chemosensitivity to Cisplatin in Oral Squamous Cell Carcinoma Cells
por: Sun, Lichun, et al.
Publicado: (2021)

Cytotoxicity of thymoquinone alone or in combination with cisplatin (CDDP) against oral squamous cell carcinoma in vitro
por: Alaufi, Omar M., et al.
Publicado: (2017)

MicroRNA-1 inhibits tumorigenicity of esophageal squamous cell carcinoma and enhances sensitivity to gefitinib
por: Yu, Qianqian, et al.
Publicado: (2018)

Cisplatin Plus Cetuximab Inhibits Cisplatin-Resistant Human Oral Squamous Cell Carcinoma Cell Migration and Proliferation but Does Not Enhance Apoptosis
por: Choi, Hyeong Sim, et al.
Publicado: (2021)

Significant increase in hEGF uptake is correlated with formation of EGFR dimers induced by the EGFR tyrosine kinase inhibitor gefitinib
por: He, Peng, et al.
Publicado: (2013)

58. The Epidermal Growth Factor Receptor (EGFR) Inhibitor Gefitinib Enhances In Vitro and In Vivo Peripheral Nerve Regeneration in a Mouse Median Nerve Injury Model
por: Topley, Max, et al.
Publicado: (2023)

Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII
por: Pedersen, M W, et al.
Publicado: (2005)

Mitochondrial DNA alterations may influence the cisplatin responsiveness of oral squamous cell carcinoma
por: Aminuddin, Amnani, et al.
Publicado: (2020)

Efficacy and safety of EGFR inhibitor gefitinib in recurrent or metastatic cervical cancer: a preliminary report
por: Krishna, Abhishek, et al.
Publicado: (2023)

Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib
por: WANG, XINZHAO, et al.
Publicado: (2015)

Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKT inhibitor MK2206 in mammary cancer models
por: Lubet, Ronald A., et al.
Publicado: (2018)

Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKT inhibitor MK2206 in mammary cancer models
por: Lubet, Ronald A., et al.
Publicado: (2019)

In Vitro Study of Synergic Effect of Cisplatin and Low Molecular Weight Heparin on Oral Squamous Cell Carcinoma
por: Camacho-Alonso, Fabio, et al.
Publicado: (2020)

Exosomes derived from gefitinib-treated EGFR-mutant lung cancer cells alter cisplatin sensitivity via up-regulating autophagy
por: Li, Xiao-Qiu, et al.
Publicado: (2016)

The Differential Metabolic Response of Oral Squamous Cell Carcinoma Cells and Normal Oral Epithelial Cells to Cisplatin Exposure
por: Chen, Xun, et al.
Publicado: (2022)

Bmi1 Essentially Mediates Podocalyxin-Enhanced Cisplatin Chemoresistance in Oral Tongue Squamous Cell Carcinoma
por: Zhou, Yueying, et al.
Publicado: (2015)

Response to gefitinib/crizotinib combination in a pulmonary sarcomatoid carcinoma patient harboring concurrent EGFR mutation and MET amplification
por: Wang, Xiaomeng, et al.
Publicado: (2021)

EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells
por: Gong, Hao, et al.
Publicado: (2020)

Gefitinib-mediated apoptosis is enhanced via inhibition of autophagy by chloroquine diphosphate in cutaneous squamous cell carcinoma cells
por: Wang, Jianyu, et al.
Publicado: (2019)

Author Correction: Mitochondrial DNA alterations may influence the cisplatin responsiveness of oral squamous cell carcinoma
por: Aminuddin, Amnani, et al.
Publicado: (2021)

AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations
por: Zhao, Ren, et al.
Publicado: (2016)

Extracellular Vesicle miR-200c Enhances Gefitinib Sensitivity in Heterogeneous EGFR-Mutant NSCLC
por: Lin, Chien-Chung, et al.
Publicado: (2021)

Osteopontin Involves Cisplatin Resistance and Poor Prognosis in Oral Squamous Cell Carcinoma
por: Luo, Sheng-Dean, et al.
Publicado: (2015)

Overexpression of β-Catenin Induces Cisplatin Resistance in Oral Squamous Cell Carcinoma
por: Li, Long, et al.
Publicado: (2016)

The Molecular Basis and Therapeutic Aspects of Cisplatin Resistance in Oral Squamous Cell Carcinoma
por: Cheng, Yali, et al.
Publicado: (2021)

LPIN1 Induces Gefitinib Resistance in EGFR Inhibitor-Resistant Non-Small Cell Lung Cancer Cells
por: Cho, Jung Hee, et al.
Publicado: (2022)

Lung squamous cell carcinoma with brachial soft tissue metastasis responsive to gefitinib: Report of a rare case
por: Kataoka, Kana, et al.
Publicado: (2016)

Acquired Gefitinib-Resistant Mutation of EGFR in a Chemonaive Lung Adenocarcinoma Harboring Gefitinib-Sensitive Mutation L858R
por: Gow, Chien-Hung, et al.
Publicado: (2005)

Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction
por: Wang, Wen-Ping, et al.
Publicado: (2012)

Role of Endocytosis Proteins in Gefitinib-Mediated EGFR Internalisation in Glioma Cells
por: Cruz Da Silva, Elisabete, et al.
Publicado: (2021)

Enhancement of Cisplatin Cytotoxicity by Cu(II)–Mn(II) Schiff Base Tetradentate Complex in Human Oral Squamous Cell Carcinoma
por: Al-Serwi, Rasha H., et al.
Publicado: (2020)

A PLK1 kinase inhibitor enhances the chemosensitivity of cisplatin by inducing pyroptosis in oesophageal squamous cell carcinoma
por: Wu, Mengjiao, et al.
Publicado: (2019)

Metformin inhibited esophageal squamous cell carcinoma proliferation in vitro and in vivo and enhanced the anti-cancer effect of cisplatin
por: Wang, Feng, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_gkeeon60kptb3ple0s8skbjho6